Antiphospholipid Syndrome: DOACs vs. Warfarin
Wednesday, January 9, 2019, 12:00 PM ET

Guest Speakers:
David Garcia, MD and Vittorio Pengo, MD

AC Forum Moderators:
Tracy Minichiello, MD; Michael Streiff, MD; Diane Wirth, ANP, CACP

This webinar will use a case-based approach to review diagnosis and management of Antiphospholipid Syndrome and discuss the results of the TRAPS study. Combining highlights from two recent articles on APS, Diagnosis and Management of the Antiphospholipid Syndrome and Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome this session will provide a practical overview of this complicated topic.

Lead authors Dr. David Garcia and Dr. Vittorio Pengo will join our panel of AC Forum experts for this webinar.

Register Now!
Abstract Update

Thank you to all those who submitted abstracts for review. Notifications went out last week to the submitting author. If you were the submitting author and didn't receive notification, please check your spam folder. If you don't see a notification in spam, please let us know at egoldstein@acforum.org.

Scholarship Recipients

We had an overwhelming response with many very strong applications. We are impressed with the caliber of the applicants and their commitment to enhancing patient care. We are pleased to be able to increase the number of scholarships awarded to the following 14 people. Our scholarship recipients represent 5 countries.

Congratulations to our scholarship recipients:

- Tamrat Assefa, Ethiopia
- Muhammad Awais, Pakistan
- Ana Baue, United States
- Youssef Bessada, United States
- Whitney Birney, United States
- Trevor Gardner, United States
- Heidi Grebe, United States
- Jennifer Hehn, United States
- Holly Jahn, United States
- John Kanyi, Kenya
- Kimberly Lavoie, United States
- Marit Mark, Estonia
- Allison Riendeau, United States
- Jacqueline Tomanek-Stanley, United States
We were also able to award partial scholarships of complimentary registration to 10 additional applicants.

Haven't registered yet? Check out our [program](#) and [faculty](#) and reserve your spot today!

---

**AC Forum Andexanet Survey Results**

The Anticoagulation Forum recently disseminated a brief member survey soliciting information regarding their hospital's access to and handling of andexanet alfa. *Thank you those who participated in this study.* Between 9/21 and 11/20 we received 53 responses and some of the key findings include:

Responding hospitals that **have** added andexanet to formulary:
- 12 of 53 of respondents (23%)
  - 3 were original study sites
  - 9 were approached by the manufacturer
- All 12 hospitals store andexanet in main pharmacy (1 also in ED)
- Approved use(s) primarily limited to any major bleed, ICH, GIB
  - 2 hospitals restrict to only ICH (17%)
  - 5 allow use for emergent surgical procedures (42%)
- 8 hospitals restrictions prescribing to attendings or specialty services via consult (67%)
- 9 of 11 reported additional pharmacy review/approval processes, ongoing Pharmacy and Therapeutics (P&T) medication utilization reviews (MUE), and escalation of inappropriate prescribing to medical executives (82%)
- The number of doses administered since formulary addition range from 0 to 16

Responding hospitals that **have not** added andexanet to formulary:
- 41 of 53 respondents (~77%)
- Reasons for not adding to formulary include
  - Not available (n=15; 37%)
  - Cost concern (n=27; 66%)
  - Operational/turnaround concern (n=15; 37%)
  - Lack of strong outcomes data (n=10; 24%)
- Agents currently used for FXa reversal
  - 3-factor PCC (n=1; 2%)
  - Activated PCC (n=2; 5%)
  - Fixed-dose 4-factor PP (n=9/41; 22%)
  - Weight-based 4-factor PCC (29; 71%)

This survey highlights the real-world challenges and concerns regarding the acquisition and operationalization of andexanet alfa. The Anticoagulation Forum appreciates the responses of the participating members and will continue to identify and share relevant information on this important topic.

---

**Thank you to our newsletter sponsors**